Clinical trials: Leukemia Acute Myeloid - AML
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
To evaluate the efficacy of PEG-BCT-100 in patients with relapsed or refractory acute myeloid leukemia (AML) in terms of remission rate.
- Trial name
- NCT02899286
- Testing
- PEG-BCT-100
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Bio-Cancer Treatment International Limited
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT04708054
- Testing
- Busulfan, Cladribine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
The purpose of this study is to determine the maximal tolerated dose (MTD) of bortezomib and idarubicin given in combination to newly diagnosed AML patients >60 years or relapsed AML patients.
- Trial name
- NCT00382954
- Testing
- Velcade, Idarubicin
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Kentucky
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome)
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
AlloHeme is a blood-based monitoring test developed by the CareDx laboratory that utilizes NGS technology coupled with a proprietary algorithm to predict the likelihood of a relapse in post-allo-HCT AML/MDS patients.
- Conditions
- AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML
- Trial name
- FORWARD (NCT07607327)
- Testing
- AlloHeme
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- CareDx
Acute Myeloid Leukemia, AML With FLT3 Mutation
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
The goal of this clinical trial is to learn if gilteritinib-azacitidine-venetoclax combination drug therapy works to treat adults with FLT3-wt acute myeloid leukemia (AML).
- Trial name
- GAVE001 (NCT07755202)
- Testing
- gilteritinib-azacitidine-venetoclax
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Florian Kuchenbauer
Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML.
- Trial name
- NCT00715637
- Testing
- Daunorubicin and Cytarabine, Amonafide and Cytarabine
- Where
- 158 sites in United States, Argentina and 21 more
- Volunteers
- 420 people
- Sponsor
- Antisoma Research
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This randomized phase II trial is studying two different schedules of alvocidib to compare how well they work when given together with cytarabine and mitoxantrone in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00795002
- Testing
- alvocidib, mitoxantrone hydrochloride, cytarabine
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, AML, Childhood
AflacLL1901 (CHOA-AML)
The investigators propose to study an Aflac-AML chemotherapy backbone prospectively to validate its use in all pediatric AML and to further evaluate the cardiotoxicity with this approach for low risk AML.
- Trial name
- NCT04326439
- Testing
- Cytarabine, Daunorubicin, Erwinase
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
AML, FLT3-ITD Mutation
Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
The study aims to test if combination of quizartinib (AC220) and omacetaxine mepesuccinate (OM, also known as homoharringtonine) results in durable composite complete remission (CRc) in patients with newly diagnosed or…
- Trial name
- NCT03135054
- Testing
- Quizartinib, Omacetaxine Mepesuccinate Injection
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Acute Leukemia, Acute Lymphoblastic Leukemia
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
Mortality in case of SARS-CoV-2 infection (Covid-19) during acute leukemia (AL) treatment is around 30%, i.e. more than 10 times the one of general population. Severe forms are reported in children receiving chemotherapy for AL.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- PACIFIC (NCT04969601)
- Testing
- vaccine COMIRNATY® (BNT162b2)
- Where
- 2 sites in France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
CAV Regimen for R/R AML
This study aims to investigate the efficacy and safety of cladribine, combined with low-dose cytarabine and venetoclax (CAV regimen) for relapsed/refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT05657639
- Testing
- CAV Regimen, MEC Regimen
- Where
- China
- Volunteers
- 68 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Acute Myeloid Leukemia
Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.
In this phase clinical trail, we evaluate the efficacy and feasibility of azacytidine and venetoclax as leukemia debulking treatment followed by reduced intensity conditioning regimen consisting of Fludarabine + Busulfan +…
- Trial name
- NCT04904237
- Testing
- Aza-Ven-allo-HSCT
- Where
- 3 sites in China
- Volunteers
- 23 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
AML, Adult, Myelodysplastic Syndromes
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive…
- Trial name
- EPITHINK (NCT03612739)
- Testing
- NKR-2 CAR-T Cells
- Sponsor
- Celyad Oncology SA
Acute Myeloid Leukemia
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
- Trial name
- VALOR (NCT01191801)
- Testing
- vosaroxin + cytarabine
- Where
- 124 sites in United States, Australia and 13 more
- Volunteers
- 711 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in…
- Trial name
- NCT00655395
- Testing
- Laromustine (VNP40101M) and Ara-C
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Viron Therapeutics Inc
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when given together with fludarabine and cytarabine for the treatment of patients with leukemia that has come back (relapsed) or has not…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04526795
- Testing
- Cytarabine, Fludarabine, Pegcrisantaspase
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia
Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies
Prognosis of patients undergoing salvage allogeneic stem cell transplantation for refractory leukemia or other refractory myeloid malignanies is poor.
- Conditions
- Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- PTBCy (NCT04943757)
- Testing
- Bendamustine Hydrochloride, Cyclophosphamid
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.